AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2003 FEB 12 - (NewsRx.com & NewsRx.net) -- Researchers in Japan have identified a method for improving the protection afforded by Mycobacterium bovis bacillus Calmette-Guerin (rBCG)-based HIV vaccines.
An effective rBCG-based vaccine will have to elicit "high levels of HIV-1-specific immunity while at the same time maintaining immunity to tuberculosis," explained M. Kawahara and colleagues, National Institute of Infectious Diseases.
The researchers investigated "a combined vaccination strategy for enhancement of immune responses specific for HIV-1," according to their report. "Guinea pigs were inoculated with either a single or combination intradermal (i.d), intrarectal (i.r.) and intranasal (i.n.) administration of rBCG-pSOV3J1 which secretes a chimeric protein of HIV-1 V3J1 peptide and alpha-antigen."
"Significant levels of delayed-type hypersensitivity to both V3J1 peptide and tuberculin was induced in guinea pigs inoculated with human doses of rBCG-pSOV3J1 by a combination of intrarectal and intradermal routes," study data showed. "Guinea pigs inoculated by combined routes also had significantly higher titers of HIV-1-specific serum IgG and IgA compared with those animals immunized only intrarectally, which led to the enhanced neutralization activity against HIV-1(MN)."
...Source: HighBeam Research, Combined intrarectal/intradermal inoculation boosts M. bovis-based...